is listed at the Spotlight Stock Market since 2012.
Our ticker: RESP
Equity Analyst: Arvid Necander
Latest research on Respiratorius https://www.redeye.se/company/respiratorius
Rights issue 2020-2021 (Swedish). Read more
Respiratorius AB (publ) develops candidate drugs with the goal of launching drugs to treat aggressive lymphoma (cancer).
Scheeletorget 1, 223 81 Lund, Sweden
+46 70 922 41 40